Park Place Capital Corp Increases Stock Position in Sanofi (NASDAQ:SNY)

Park Place Capital Corp grew its holdings in shares of Sanofi (NASDAQ:SNY) by 6.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,068 shares of the company’s stock after buying an additional 534 shares during the quarter. Park Place Capital Corp’s holdings in Sanofi were worth $441,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Dynamic Advisor Solutions LLC purchased a new stake in Sanofi in the 4th quarter worth about $2,104,000. Vestal Point Capital LP purchased a new stake in Sanofi during the fourth quarter valued at approximately $14,919,000. Oxbow Advisors LLC purchased a new stake in Sanofi during the fourth quarter valued at approximately $4,689,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Sanofi by 348.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 32,456 shares of the company’s stock worth $1,614,000 after buying an additional 25,213 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in shares of Sanofi in the fourth quarter worth $4,704,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 2.2 %

SNY stock opened at $49.59 on Tuesday. The firm has a market cap of $125.60 billion, a PE ratio of 24.92, a P/E/G ratio of 1.50 and a beta of 0.59. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm’s fifty day moving average is $48.68 and its 200 day moving average is $48.57. Sanofi has a one year low of $42.63 and a one year high of $55.72.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.96. The business had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. On average, research analysts forecast that Sanofi will post 4.13 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.